Abhijit R

  • Medical Implants Sterile Packaging Market 2017 | Industry Growth, Size, Outlook, 2025

    Thermoform Engineered Quality has developed a new solution—TEQpropylene that is intended to reduce sterile packaging costs and harmful environmental impacts. The strength, sustainability, and clarity improvements of TEQpropylene offers cost-effective packaging. Moreover, pouches made by Tyvek are used for packaging various sterilized medical devices, particularly those devices that are low profile and light weight. Sterilization pouches made by Tyvek are used in outpatient surgical centers and in house sterilization of surgical instruments, owing to its resistance to microbial penetration. Such resistance aid in retaining sterility of contents in pouches until opened. Moreover, Tyvek pouches provide superior puncture resistance and tear strength as compared to medical-grade papers, which is a major factor contributing to increase in demand for its use in sterilization of medical devices.

    The global medical implants sterile packaging industry over the last few decades have observed a notable growth due to significant increase in the number of implant products. Medical implants sterile packaging has been widely used in the packaging of joint, spinal, and support implants, owing to anti contaminant and high-performance factors. Sterile packaging plays a vital role in the life-saving pharmaceuticals drugs and medical devices.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/995

    However, there are other implants, which deliver medication, provide support to tissues and organs, and monitor body functions. Clamshell pack is one of the fastest growing segments in the medical implants sterile packaging market. Clamshell packaging has numerous advantages with respect to appearance, portability, and convenience. It is mainly used to pack various medical and surgical appliances and instruments.

    According to American Association of Oral and Maxillofacial Surgeons, in 2014, around 69% of adults aged between 35 and 44 have lost at least one permanent tooth due to unsuccessful root canal, to an accident or by tooth decay. Thus, there is a rise in the practice of dental implants placed each year by 100,000 to 300,000, which is similar to the numbers of artificial knee and hip joints placed per year.

    Furthermore, rising prevalence of chronic degenerative diseases and stringent regulations pertaining to sterilization of medical device packaging are the other factors that drive the growth of the medical implant sterile packaging market. However, inappropriate packaging of boxes for medical devices contaminate the devices while transportation and storage causing financial loss thereby, hindering the growth of medical device sterile packaging market.

    Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/995

    Detailed Segmentation:

    By Product Type:

    Clamshell

    Pouches and Bags

    Blisters

    Tubes

    Vials

    Others

    By Application:

    Spinal Implants

    Reconstructive Joint Implants

    Hip Joints

    Knee Joints

    Elbow Joints

    Others

    Extremity Braces and Support

    Knee

    Foot/Ankle

    Hand

    Elbow/Wrist

    Dental Implants

    Cardiovascular Implants

    Others

    By Material Type:

    Plastic

    Paper

    Foils

    Others

    The major players in medical implants sterile packaging market are Beacon, SteriPack, Wipak, Oliver- Tolas, Rexam, Oracle Packaging, Riverside Medical Packaging, West Pharmaceutical Services, Amcor, Rollprint Packaging Products, and Sealed Air Corporation. The key players are focusing on strategic mergers and acquisition and development of innovative packaging systems.

    For instance, Amcor has launched an innovative packaging technology in 2016, known as Fortis sterile breather bag (an uncoated Tyvek header bag), which delivers strength, sustainability, and tear resistance to hold sharp, heavy, and bulky packs in contrast to conventional header bags. Fortis header bags opening allows aseptic removal of contents easier thereby, reduces the risk of contamination to the sterile field.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/995

    Some of the major players involved in global medical implants sterile packaging market are Beacon, SteriPack, Wipak, Oliver- Tolas, Rexam, Oracle Packaging, Riverside Medical Packaging, West Pharmaceutical Services, Amcor, Rollprint Packaging Products, and Sealed Air Corporation.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Hemodynamic Monitoring Systems Market 2017 - Industry Growth, Size, Trends and Forecast to 2025

    Hemodynamics monitoring systems market is expected to gain significant traction over the forecast period, owing to launch of novel monitoring systems by manufacturers. For instance, in 2016, Siemens Healthineers launched a new version of Sensis hemodynamic system at the Annual Scientific Session and Expo of the American College of Cardiology (ACC). Sensis Vibe aids in hemodynamic recording and documentation system in the cardiovascular hybrid operating room (OR) with the new HemoBox signal input unit.

    Non-invasive and minimally invasive monitoring systems are gaining significant traction, as the use of non-invasive technique proves to be beneficial to determine the health condition of the patient and decide whether the patient can benefit from invasive techniques or the monitoring can suffice with the use of non-invasive techniques itself. Manufacturers are therefore, focused towards manufacturing systems that are novel with innovative technologies, in order to maintain their position in the market.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1070

    For instance, in June 2014, Edwards Lifesciences Corporation received U.S. Food and Drug Administration’s (FDA) clearance for its hemodynamic monitoring ClearSight system, which is a non-invasive monitor that provides clinicians access to blood volume and blood flow information for patients at moderate or high risk of post-surgical complications. In March 2017, LiDCO Group Plc introduced its next generation monitor platform in Europe. In addition to the sleek new look, the product has significant improvements in operating system and graphical user interface, and has next version of unity software with added features and functionality. In September 2017, Fysicon received FDA approval for QMAPP hemodynamic monitoring system that features up to 32 bipolar intra-cardiac channels for electrophysiology procedures.

    Market players are focused on expansion of their product portfolio and geographic reach by adoption of inorganic strategies such as mergers and acquisitions, to maintain their positions in the market. For instance, in July 2016, Cheetah Medical signed a supplier agreement with Allina Health, which is a not-for-profit healthcare system that runs hospital network in areas such as Minnesota and western Wisconsin. Through this contract, Cheetah Medical would provide hemodynamic monitoring solutions to guide volume management decisions in septic patients across the Allina Health hospital network.

    Moreover, in May 2016, LiDCO and ICU Medical signed distribution agreement to sell the LiDCO IM non-invasive hemodynamic monitoring system in U.S. LiDCO IM is a specially configured hemodynamic monitor produced exclusively for ICU Medical that works solely in conjunction with LiDCO’s non-invasive module.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1070

    Detailed Segmentation:

    By Product Type:

    Monitoring Systems

    Disposables

    Probes

    Airflow Sensors

    Others

    By Monitoring Type:

    Invasive Hemodynamics Monitoring

    Non-Invasive Hemodynamic Monitoring

    Minimally Invasive Hemodynamic Monitoring

    By End User:

    Hospitals

    Catheterization Labs

    Ambulatory Surgical Centers

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1070

    Key players are focusing on developing novel and innovative products, to sustain in the hemodynamics monitoring systems market. For instance, in March 2017, Teleflex announced 510(k) clearance by the Food and Drug Administration and both the U.S. and international commercial launch of the Twin-Pass Torque Dual Access Catheter. Moreover, in May 2016, Deltex Medical Group Plc introduced TruFlow in the U.K., which is wider beam, single patient disposable probe, the reconfigured probe tip design that creates a wider ultrasound beam at the focal point in the aorta.

    Key players operating the global hemodynamics monitoring systems market include Edwards Lifescience Corporation, LiDCO Group, Plc, PULSION Medical Systems SE, Cheetah Medical, Inc. ICU Medical, Inc., Deltex Medical Group Plc, and Teleflex, Inc.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Endocrine Testing Market - Industry Growth, Size, Share, Outlook and Forecast 2018-2026

    Companies are launching innovative products to cater the end user need and increase the market footprint in the endocrine testing market. In 2017, Beckman Coulter Diagnostics received FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic (IVD) use. AMH test helps healthcare providers in the assessment of a woman's ovarian reserve, thereby aid in the clinical management of women facing infertility or women planning to become pregnant later in life. The Access AMH assay is a paramagnetic particle chemiluminescent immunoassay for the quantitative determination of AMH levels. The test can be used in conjunction with other clinical and laboratory findings such as antral follicle count, before starting fertility therapy. Companies are also undergoing strategic collaboration to increase market share. For instance, in 2017, Quest diagnostics and Walmart collaborated, under which Quest would open laboratory testing services at 15 Walmart locations initially to gradually increase same.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1755

    Endocrine testing allows profiling of blood concentration of the various endocrine hormone. Over secretion and under secretion of endocrinal hormones results in to development of endocrinal disease. Various endocrinal disease such as hypothyroidism, hyperthyroidism, infertility, polycystic ovarian syndrome, hypo/hyperadrenocorticism, hypogonadism, diabetes, Multiple endocrine neoplasia I and II, Cushing’s disease, Gigantism (acromegaly) and other growth hormone problem and precocious puberty( Early Puberty). Endocrine diseases are caused due to various reasons such as problem in endocrine feedback system, disease condition, and failure of stimulation of glands to release hormones, tumor of an endocrine gland, genetic disorders, infection and physical trauma to an endocrine gland.

    Increasing prevalence of these disease especially hypothyroidism, infertility, and diabetes are expected to drive growth of the global endocrinal testing market. According to study published by Centre for Disease Control and Prevention (CDC), in 2017, around 100 million (30.3 million diabetes and 84.1 million prediabetes) U.S. adults were suffering from diabetes or prediabetes condition. According to American Thyroid Association, 2017, around 12% of U.S. adults are estimated to develop thyroid disease in their lifetime. Postmenopausal osteoporosis caused due to reduced estrogen production after menopause leading to low bone mineral density and increased risk for fracture risks. It is estimated that osteoporosis affects around 10 million American adults annually, 34 million people are at high risk of it due to low bone mass, according to study published by BMC Endocrine Disorder in February 2018.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1755

    Key players are undergoing strategic mergers, acquisitions, and collaborations in order to maintain leading position in market and to tap the new market. In August 2017, North West London Pathology under National Health Service Trust and Abbott Laboratories signed contract worth US$ 252 million under which Abbott Laboratories will supply all analytical equipment and consumables, this contract would manage 26 million tests annually. In 2017, Abbott Laboratories received the U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinity ci-series instruments for clinical chemistry and immunoassay diagnostics. In April 2018, Beckman Coulter launched its Access Sensitive Estradiol assay in the U.S. market, also made available its assay in the most of global markets. This test accurately detects estradiol levels in women, children, and men using low sample. Company also launched Anti-Müllerian Hormone (AMH) assay in 2017, which helps in clinical management of women suffering from infertility. In 2016, company received FDA clearance and commercially launched new Access TSH (3rd IS) assay.

    Key players operating in the endocrine testing market include Abbott Laboratories, Thermo Fisher Scientific, Beckman Coulter, Inc., Siemens Healthineers, bioMérieux SA, Agilent Technologies, Bi-Rad Laboratories, AB Sciex, F-Hoffmann La Roche AG, Quest Diagnostics, and others.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1755

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Pediatric Nutrition Market - Industry Growth, Size, Share, Trends, and Forecast 2017-2025

    Pediatric nutrition is an important source of nutritional supplement for babies during their formative years. These products are available in milk-based, Soy-based, amino acid-based, and organic forms. These nutritional products support brain development and also helps in the management of allergies and metabolic disorder. Highest number of births are recorded in Asia Pacific, and hence, the region holds maximum opportunity for market players. Due to this, companies such as Mead Johnson Nutrition (acquired by Reckitt Benckiser Group plc), Nestle S.A., and Abbott are trying to maximize their market share in Asia Pacific, especially in China. High return on investments in this market is influencing large players to opt for inorganic methods of growth, as well as increasing the entry of new players in the market. For instance, Reckitt Benckiser Group plc acquired Mead Johnson Nutrition Company in June 2017.

    Lactose intolerance, allergy to cow’s protein milk, maple syrup urine disease, phenylketonuria, and insulin resistance are some of the most common health complications faced by infants and children. These children require special nutrition, which can be provided by nutritional products. Mead Johnson Nutrition (acquired by Reckitt Benckiser Group Plc) developed a separate category of products specifically designed for children suffering from such diseases. These products include Mead Johnson BCAD, for children suffering from maple syrup urine disease and Mead Johnson PhenylFree, for children suffering from phenylketonuria. Other players such as Nestle S.A. and Abbott Laboratories also sell product for children with special needs.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1308

    Increasing number of products to serve this special population coupled with increasing awareness about such diseases is expected to support growth of the global pediatric nutrition market. Furthermore, companies are focusing on development of products that may serve as nutrition enhancer or taste modifier, for the general population. Such products include ChocoMilk and Cal-C-Tose, which when added to milk enhance its nutritional value.

    The four leading players holding a dominant position in the market are Reckitt Benckiser Group Plc, Nestlé S.A., Abbott Laboratories, and Groupe Danone, owing to a spree of market consolidation. Manufacturers are focusing on inorganic growth strategies such as mergers and acquisitions to strengthen their foothold in the global market. For instance, in 2012, Nestle S.A. acquired Pfizer Inc.’s infant nutrition business. In June 2017, Reckitt Benckiser Group Plc acquired Mead Johnson Nutrition, a leading player in pediatric nutrition.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1308

    Moreover, continuous effort from non-government organizations such as WHO, Save The Children, UNICEF and other similar minded organizations to end malnutrition has resulted in formulation of policy that recognizes the importance of nutritional products at very early age, and hence, supports this. For instance, National Nutrition Strategy formulation by Government of India in 2017. These favorable policies is expected to support growth in adoption rate for pediatric nutrition products which in turn will result in growth in the market.

    Companies in the pediatric nutrition market are increasingly focusing on inorganic growth strategies. In 2013, Nestle S.A. acquired U.S.-based Pamlab L.L.C., Covington, La., a medical nutrition company, to broaden its brain health and metabolic health portfolio. Moreover, the company has made strategic investment in companies working on similar product lines. For instance, Nestle S.A. entered into a strategic collaboration with DBV Technologies, to develop a patch-test tool for diagnosis of Cow’s Milk Protein Allergy (CMPA) for infants, in 2016.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1308

    Major players operating in the pediatric nutrition market include Reckitt Benckiser Group Plc, Nestlé S.A., Abbott Laboratories, Groupe Danone, Royal FrieslandCampina, Baxter International Inc., Fresenius Kabi, and B. Braun Melsungen AG

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Enzyme Linked Immunosorbent Assay Market - Industry Growth, Size and Forecast 2017-2025

    According to the National Cancer Institute, cancer has a major impact on the population of U.S. and across the world. The NCI reports approximately 1,685,210 new cases of cancer were diagnosed in 2016. Also, reports demand for efficient detection tests that can be sufficed with the help of ELISA test kits. Moreover, increasing demand for cost-effective diagnostic tool is one of the factor aiding the growth of ELISA market, especially in the low and middle income economies.

    For instance, in October 2017, the Nigerian government and World Health Organization (WHO) launched a campaign to vaccinate around 874,000 people against yellow fever in two states of the country Kwara and Kogi in alliance with the International Coordination Group. The samples of the patients suspected with yellow fever were further tested with the help of ELISA test at the Pasteur Institute in Dakar. However, availability of alternate immunoassays and cross reactivity projected by these tests can hinder the market growth. Development of cost-effective ELISA tests with improved reliability and accuracy can provide potential opportunity for market players to strategize their growth in the global ELISA market.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1505

    Extensive research and development in the field of immunoassay and diagnostics is leading to increasing applications and novel approaches for incorporation of ELISA in various medical fields. This has resulted in expansion of the range of Enzyme Linked Immunosorbent Assay (ELISA) products used in clinical and medical approaches.

    For instance, Inova Diagnostics, in November 2016, received U.S. FDA approval for QUANTA Lite, a Calprotectin Extended range of quantitative ELISA assay that aids in the diagnosis of Inflammatory Bowel Disease (IBD) and helps to differentiate IBD from Irritable Bowel Syndrome (IBS). Moreover, a recent test is developed by Center for Infection and Immunity at University of Columbia in March 2018, extends a window for accurate detection of Zika infection, which is complex with molecular diagnostics procedures.

    The new ZIKV-NS2B-concat ELISA is a faster, less expensive blood test, and clinical tool for accurate detection of Zika from weeks to months after onset of infection facilitating a powerful tool for the clinicians to make quick decisions for their patients. In July 2015, Bio-Rad Laboratories, Inc. received the U.S. Food and Drug Administration pre-market approval for BioPlex 2200 HIV Ag-Ab assay, which is the company's fifth generation HIV diagnostic test that produced efficient diagnostic test results for HIV.

    For instance, in March 2017, Thermo Fisher Scientific, Inc. acquired Core Informatics and added it to analytical Instruments segment to strengthen its existing informatics solutions and bio production offerings. Furthermore, the company players are also focusing on research and development for introducing novel ELISA assays and test kits in to the market to stand out and retain their positions in the market.

    Purchase Copy of This Business Research Report:  https://www.coherentmarketinsights.com/insight/buy-now/1505

    The key players operating in global Enzyme Linked Immunosorbent Assay (ELISA) Market include Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc., Biomerieux S.A., Alpco, BioLegand, Inc., Zeus Scientific, Inc., and Shenzhen YHLO Biotech Co., Ltd.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Molecular Diagnostics Market - Industry Insights, Size, Share and Forecast 2017-2025

    Molecular diagnostic test are done for diagnosis and drug discovery & development purpose. Molecular diagnostic test results are quick and accurate, which has led to increasing demand for these. In order to cater to growing demand for such tests, manufacturers are more focused on research & development for new product launches.

    For instance, in February 2017, AITbiotech Pte Ltd., a Singapore-based genomic service and molecular diagnostics (MDx) company, exhibited its comprehensive range of abTES MDx assays, including its newly launched Zika assays and the multiplex respiratory panel, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the Middle East.

    Furthermore, in October 2017, FDA approved Roche’s cobas Zika, as first commercially-available donor screening test for Zika virus. In October 2017, QIAGEN launched the custom solution for the molecular diagnostic test, which accelerated adoption of molecular testing for life sciences and molecular diagnostics companies.

    Free Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1545

    In March 2017, Cepheid, Rutgers New Jersey Medical School and FIND announced a new version of the Xpert MTB/RIF test, the Xpert MTB/RIF Ultra (Ultra), for the diagnosis of TB and rifampicin resistance. In August 2017, Selfdiagnostics launched the STD Multitest at MEDICA 2017. STD Multitest is the first and only rapid chlamydia and gonorrhoea duplex disposable molecular test in the world.

    In July 2017, Roche announced commercial availability of the cobas HIV-1/HIV-2 for use on the automated cobas 6800/8800 Systems in countries accepting the CE mark. In July 2017, DiaSorin launched a new CE-IVD molecular diagnostic test, Iam CBFB-MYH11 (not available in the U.S.) for ultra-rapid identification of one of the most common genetic causes of Acute Myeloid Leukemia (AML).Therefore, these increasing product launches in molecular diagnostics is expected to foster growth of the market in the near future.

    Key players in the market are involved in new product launches to cater to increasing demand for molecular diagnostic. For instance, in August 2016 Abbott Laboratories introduced Alinity, a next generation system, used for immunoassay, clinical chemistry, point-of-care, hematology, blood and plasma screening, and molecular diagnostics.

    Some of the other key players in the global molecular diagnostics market include Hologic,Inc., Grifols, S.A., Abbott Laboratories, Qiagen N.V., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, and Beckman Coulter, Inc.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1545

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Botanical and Plant Derived Drugs Market - Size, Share, Outlook, and Analysis, 2018-2026

    The global botanical and plant derived drugs market is projected to witness significant growth over the forecast period, owing to legalization of medical cannabis. Medical cannabis was legalized in the Czech Republic, in 2013, Argentina and Chile in 2015, and in 2016, marijuana legalization in America reached a tipping point, as the medical marijuana became legal in some of the states.

    Hence, many manufacturers are focused on research and development on medical cannabis to launch new drugs. For instance, one of the drug by GW Pharmaceuticals, Epidiolex consists of cannabidivarin (CBDV) is in developmental process, which will be used in clinical trials for treatment resistant epilepsy, supported by NSW and Queensland government in 2016.

    Furthermore, increasing number of chronic disease supports the growth of botanical and plant derived drugs, as lung cancer accounts for the leading cause of death in the Eastern, Southern and Southeastern Asia. The region holds for 56% of the world’s population and contributes to 44% of the total cancer cases worldwide according to the statistics mentioned in the Cancer Atlas.

    Free Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1737

    For instance, one of the drug by GW Pharmaceuticals, Epidiolex drug consists of cannabidivarin (CBDV) is in developmental process, which will be used in clinical trials for treatment resistant epilepsy, supported by NSW and Queensland government in 2016. Moreover, Insys Therapeutics, an America-based company have Subsys drug in their product portfolio, which is prescribed for the treatment of advanced pain associated with cancer. The subsys is a synthetic version of cannabidiol (CBD) and has accounted for almost 100% of the company’s 2014 year-to-date revenue.

    Increasing applications of botanical and plant derived drugs are receiving regulatory approvals with respect to cancer patients - as a cure and as a supplement to current treatments, which provides a great opportunity for conducting clinical trials. For instance, in June 2017, Medlab Clinical received approval to begin human trials of two different cannabis based medicines – NanaBis and NanaBidial. NanaBis is packaged as a mouth spray and will be clinically tested in advanced stage for cancer patients with intractable pain. NanaBidial comprises cannabidiol derived from marijuana and is indicated for chemotherapy induced nausea and vomiting, with a secondary endpoint in patients suffering seizures

    Key players operating in the market include Bayer Healthcare, GlaxoSmithKline, Pfizer, Inc. Sanofi, Actelion Pharmaceuticals, Aimil Pharmaceuticals, Allergan, AstraZeneca, Boehringer Ingelheim, and GW Pharmaceuticals.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1737

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Patient Flow Management Solutions Market - Outlook, and Opportunity Analysis, 2018-2026

    Increasing number of hospital admissions and shortage of healthcare professionals is expected to create more burden on the current hospital patient flow management system, thereby increasing the demand for advanced patient flow management solutions.

    A report published by Association of American Medical Colleges (AAMC) in March 2018 focuses on the scenario of shortage of heathcare physicians in both primary and specialty care. This report updates and aligns estimates conducted in 2015, 2016, and 2017, which shows a projected shortage of physicians between 42,600 and 121,300 by 2030.

    The report aggregates the shortages into four broad categories: primary care, medical specialties, surgical specialties, and other specialties. According to this report, an estimated shortfall of between 14,800 and 49,300 primary care physicians will be reported by 2030. Furthermore, for the same period, there will be a shortage in non-primary care specialties between 33,800 and 72,700 physicians.

    Furthermore, key players in the market are focused on acquisition strategies to expand their geographical presence. For instance, in October 2015, Aptean completed the acquisition of Medworxx Solutions Inc. Through the acquisition, Medworxx’s knowledge management, patient flow, and patient safety solutions portfolio for healthcare organizations was added to Aptean’s product portfolio.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/730 

    In May 2018, Allscripts Healthcare Solutions signed a definitive agreement to acquire HealthGrid Holding Company. HealthGrid is a developer of mobile patient engagement platforms, which enable providers to reach patients using existing contact information, without requiring them to sign up for a patient portal. Furthermore, under the agreement, Allscripts will integrate HealthGrid's functions into its FollowMyHealth patient engagement platform.

    In June 2017, Aptean acquired FDM Software. This acquisition enables Aptean to offer an integrated platform with hospital patient flow capabilities. FDM Software operates its business in Records Management (RMS), Computer-Aided Dispatch (CAD), mapping and analysis solutions for public safety agencies in North America and Latin America.

    In July 2018, Change Healthcare received the US$ 5.5 million grant from The Israel Innovation Authority (IIA), to expand its research and development (R&D) facility in Israel.

    In September 2018, Hyland Healthcare and Change Healthcare partnered to offer fully integrated medical claims attachment technology. This allows providers and payers to transmit claims attachment quickly and improves patient experience, optimize the revenue cycle, and reduce inefficiency and wait time.

    Major players operating in the global patient flow management solutions market include Getinge AB, Allscripts Healthcare Solutions, Inc., Cerner Corporation, McKesson Corporation, Epic Systems Corporation, Aptean, Inc., Sonitor Technologies, Inc., Stanley Black & Decker, Inc., and TeleTracking Technologies, Inc.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/730 

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Gastric and Esophageal Cancer Drugs Market - Industry Growth, and Analysis 2018-2026

    Symptoms of gastric and esophageal cancers include difficulty in swallowing (dysphagia), weight loss, chest pain, indigestion or heartburn, coughing or hoarseness, pain behind the breastbone. Early stage of gastric and esophageal cancer does not show any of this signs and symptoms.

    Increasing number of cancer drugs in pipeline studies and rising involvement of key players for development of cancer treatment are expected to propel gastric and esophageal cancer drugs market growth. For instance, in April 2016, Centre Hospitalier Universitaire de Besancon, initiated Phase 1 and Phase 2 clinical trial for Carboplatin to determine the maximum tolerated dose (MTD) and recommended doses for phase II (RP2D) by considering the treatment scheme of Dutch study for chemotherapy and radiotherapy. The study is conducted in elderly patients with esophagus cancer. Carboplatin is an anticancer chemotherapy drug from alkylating agent category. The study is estimated to complete by April 2024.

    Free Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2438

    Moreover, in February 2017, Henan Cancer Hospital in collaboration with Jiangsu HengRui Medicine Co., Ltd., initiated Phase 2 exploratory clinical trial to evaluate the efficacy of Apatinib, treatment for advanced esophagus cancer. Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2(VEGFR2).

    However, high cost of therapy for the treatment of gastric and esophageal cancers is expected to restraint the market growth. For instance, as per the report published in Healthday, in 2013, cancer patients paid US$ 207,000 a year for the treatment and medications while in 1995 the cost was US$ 54,100 a year.

    For instance, the American Cancer Society’s estimated that about 17,650 new esophageal cancer cases in the U.S. will be diagnosed (13,750 in men and 3,900 in women) by 2019. Moreover, mergers and acquisitions activities by key players in this region are expected to propel the market growth during the forecast period. For instance, in December 2018, GlaxoSmithKline plc announced the acquisition of TESARO Inc, an oncology focused company based in Massachusetts, U.S. This acquisition is expected to strengthen GSK’s pharmaceutical business by accelerating GSK’s pipeline and commercial capability in oncology.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2438

    Key players in Europe are focused on various business strategies such as acquisitions and mergers, which in turn boosts growth of the market. For instance, in September 2018, Boehringer Ingelheim acquired all shares of ViraTherapeutics, an Austria-based biopharmaceutical company, specializing in the development of oncolytic viral therapies. The total transaction value for this acquisition was US$ 240.52 million. This acquisition strengthened Boehringer Ingelheim’s commitment to research and development for viral-based immuno-oncology treatment.

    Key players for gastric and esophageal cancer drugs market includes Amgen, Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Merck & Co. and others.

    Purchase this Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/2438

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Hemorrhoid Treatment Devices Market Industry Report, Size, Share, and Analysis, 2018-2026

    Hemorrhoid is a common disease in a general population, which is also known as the piles, where the patient suffers from painless bleeding during bowel movement, itching and irritation in anal side, swelling of anal veins, pain and discomfort, and formation of lumps near to anus, which is sensitive and painful. Hemorrhoid is distinguished into two parts such as internal hemorrhoid and external hemorrhoid.

    Treatment for hemorrhoid disease includes non-surgical treatment and surgical treatment. Non-surgical treatment includes laxatives and corticosteroids. Surgical treatment includes banding, sclerotherapy, infrared coagulation, hemorrhoidectomy, and hemorrhoid sampling. Various devices are used for the treatment of hemorrhoid such as endoscopic rubber band ligator, hemorrhoidal multi-band ligator, disposable hemorrhoid banding system, mcgivney hemorrhoidal ligator, endoscopic infrared coagulator, and lumatec infrared coagulator.

    New product launches is expected to drive the global hemorrhoid treatment devices market size. For instance, in March 2019, De Scalene launched a new device called Cryocure, an affordable device to treat hemorrhoid without surgery. Cryocure helps to stop the bleeding from anal blood vessels and constriction of that anal blood vessels.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2647

    Furthermore, increasing incidence and prevalence of hemorrhoid disease in the U.S. is expected to drive the global hemorrhoid treatment devices market growth. For instance, in March 2016, according to the National Center for Biotechnology Information (NCBI), overall prevalence of hemorrhoid disease in the general population is around 4.4% and self-reported incidence of hemorrhoid disease is around 10 million persons, annually in the U.S.

    For instance, in January 2018, PRIVI MEDICAL PTE. LTD., received U.S. FDA clearance for its new device (Instalief), which is used for the hemorrhoid treatment. Instalief is the drug-free device, which provides the instant cold relief without any side-effects.

    Majority of market players in the global hemorrhoid treatment devices market such as Zhengzhou Safute Electronic Equipment Co., Ltd., and Wuxi Shenkang Medical Instrument Equipment Co. Ltd belong to China. These companies include various hemorrhoid treatment devices such as anorectal physical therapy device, SAFUTE hemorrhoid surgery device, and sigmoid colon and hemorrhoid disease treating device.

    Key players operating in the global hemorrhoid treatment device market include Johnson & Johnson, PRIVI MEDICAL PTE. LTD., Cook Medical, Medtronic Plc, Integra LifeSciences Corporation, OBP Medical Corporation, Boston Scientific Corporation, Sklar Surgical Instruments, Surkon Medical Co., Ltd., and CONMED Corporation.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2647

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Halitosis Treatment Market - Size, Share, Trends, and Forecast 2018-2026

    Halitosis or bad breath according to a National Center for Biotechnology Information (NCBI), affect half of the population in the U.S. and between 50% and 60% of the population in France. Although it occurs due to number of causes, oral hygiene is a major factor. Respiratory system problems, hepatic disease, gastrointestinal disease, hematological or endocrine system disorders, and metabolic conditions can also the cause halitosis.

    Other potential factors that contribute to halitosis are endodontic, surgical, and pathologic factors such as exposed tooth pulps and non-vital tooth with fistula draining into the mouth, oral cancer, oral cavity pathologies, and ulcerations, extractions/healing wounds or prosthetics. All these factors cause food or plaque retention area, decay of amino acids, raising bacterial amount, tissue breakdown, and decreasing of saliva flow. These conditions result in the release of volatile compounds causing halitosis.

    Treatment for bad breath can vary depending on the cause. For instance, halitosis caused due to a buildup of bacteria (plaque) on teeth can be treated with mouth rinse that kills the bacteria. Furthermore, halitosis caused due to gum diseases can be treated with tooth cleaning procedures.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2219

    Manufacturers in halitosis treatment market are focused on development and approval of new products and strategic collaborations with other industry players to gain significant market share. For instance, in 2017, Listerine, a leading market player in halitosis treatment market launched a new Green Tea variant that combines essential oils and green tea extract with fluoride.

    Increasing consumption of tobacco and alcohol, medical condition such as tonsils and inflammation of nose, throat or sinuses and metabolic diseases are the major factors driving the halitosis treatment market growth. According to the National Center for Biotechnology Information (NCBI) 2013 study, halitosis is very common and affects around 50% of the general population around the world.

    Although halitosis has multifactorial origins, around 90% cases occur due to oral cavity such as poor oral hygiene, tongue coat, periodontal disease, unclean dentures, food impaction, oral carcinomas, faulty restorations, and throat infections. Treatment of halitosis is very important, as it can cause serious conditions such as stress. According to the Bad Breath Institute 2018 study, people with halitosis are 60% more likely to suffer from stress, while 57% of bad breath sufferers report feelings of depression due to their condition. However, lack of awareness among the under developed regions can confine the halitosis treatment market growth.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2219

    Key players operating in the global halitosis treatment market include Abbott Laboratories, AstraZeneca Plc., Colgate-Palmolive Company, Dr. Harold Katz, Listerine, and Rowpar Pharmaceuticals.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Surgical and Dental Loupes Market Size, Growth | Industry Analysis, 2018-2026

    The surgical and dental loupes market growth is driven by increasing prevalence of dental problems. According to FDI World Dental Federation’s Oral Health Atlas Published in 2015, oral disease affects around 3.9 billion people worldwide, with untreated tooth decay, which impacts around 44% of world’s population. Moreover, 90% of tooth decay cases require endodontic procedures that involves surgical procedure to save the natural tooth. Rising incidence of musculoskeletal disorders related to dental anatomy and increasing utilization of restorative dentistry and endodontic practices by the utilization of dental loupes drives growth of the surgical and dental loupes market. In addition, increasing dental insurance coverage and rising number of dental procedures drives growth of the surgical and dental loupes market.

    Moreover, manufacturers and researchers are entering into partnerships, which include the agreement that allow dentists to improve patient care. For instance, in June 2013, Carl Zeiss Meditec Inc. and Henry Schein Dental announced their distribution partnership in the U.S. for ZEISS EyeMag dental loupes. This partnership facilitates the U.S. dentists to easily incorporate practice premium dental loupes for improved patient care. According to the World Health Organization’s Oral Health factsheet in 2018, the world prevalence of traumatic dental injuries in the arrangement of teeth in a particular individual is around 20%. Oral dental trauma can be caused by oral and environmental factors (unsafe playgrounds and schools).

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2771

    Geriatric population with dental problems is another major factor driving growth of the market, as they face oral health issues such as shrinkage of gums with age, leading to tooth decay or infection, loss of teeth, and poor fitting dentures. According to WHO oral health factsheet 2012, around 30% of people aged 65–74 years have no natural teeth and burden is expected to increase in the near future.

    Moreover, in November 2016, Orascoptic, a leader in superior vision solutions for dental and medical professionals, launched HDL 2.5 Micro- a 2.5x magnification power Galilean loupe with high definition resolution and substantial field of view.

    Rising healthcare expenditure, technological advancements, and increasing incidence of dental disorders in the region. According to the Centers for Disease Control and Prevention, in 2015, over 1 in 4 or 27% adults in the U.S. had untreated tooth decay. Moreover, at the 2014 Greater New York Dental Meeting in the U.S., Orascoptic launched RDH Elite loupe, which is designed with a singular focus on dental hygiene.

    Some of the key players operating in the global surgical and dental loupes market include Univet Optical Technologies, L.A. Lens, Rose Micro Solutions, Ergonoptix, Designs For Vision, PeriOptix, Enova Illumination, SheerVision Incorporated, Carl Zeiss Meditec AG, Orascoptic, and SurgiTel.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2771

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Healthcare Simulators Market Size, Trend and Forecast Till 2026

    The rising launch of high-fidelity simulators which provide the most realistic experience by the developers is a major factor propelling market growth. For instance, in February 2018, MedaPhor launched BodyWorks Eve, a high-fidelity female manikin-based simulator that can be used by medical professionals to meet educational requirements. The Point of Care Ultrasound (PoCUS) simulator can be used across emergency medicine and critical care.

    Moreover, increasing healthcare expenditure is also expected to boost adoption of medical simulators. The healthcare spending will improve quality of the healthcare services, aid in employing more practitioners, and better medical training and developed infrastructure with advanced software. For instance, according to World Health Organization, China’s healthcare market reached US$ 853.7 billion in 2016, an increase of 12% in local currency, the number projected to reach $1.1 trillion by 2020.

    Free Request Sample Copy of This Report: www.coherentmarketinsights.com/insight/request-sample/2802

    Manufacturers in the Global Healthcare Simulators market are focusing on strategic mergers and acquisitions in order to gain significant market share. For instance, in August 2014, 3D Systems acquired Simbionix which was the global leader in 3D virtual reality surgical simulation and training. This technology by Simbionix was complementary with 3D System’s product offering.

    Furthermore, the web-based simulation programs provide a valuable resource as they can be combined with classroom teaching, thereby facilitating the development of students’ clinical competence. Thus, increasing demand for web-based simulation is directly associated with the increasing number of medical institutes for providing students with clinical placement experience, especially in the field of medicine and nursing.

    However, simulators cannot mimic human systems completely. The complexity and diversity of human systems is very high and difficult to be mimicked by instruments or software, providing the inadequate information as compared to human response. Moreover, medical stimulators require technically trained professionals to guide through the learning process involved in simulation-based medical education. All such factors are expected to negatively impact the market growth over the forecast period.

    Moreover, manufacturers are launching new products in regular intervals with new technology and increasing fidelity, which is fuelling the market growth over the forecast period. For instance, in May 2018, SimMan Vascular System was developed by Laerdal Medical, in collaboration with Mentice. It includes Mentice VIST technology and is largely adopted in pre- and in-hospital team training to support acute endovascular procedures.

    Get PDF Brochure of Research Report: www.coherentmarketinsights.com/insight/request-pdf/2802

    Major players operating in the global healthcare simulators market include, Laerdal Medical, 3D Systems, Simulab Corporation, Simulaids, Inc., Kyoto Kagaku, Mentice, Medaphor, CAE Healthcare, Gaumard Scientific Company, Limbs & Things, BT, Inc., Trandomed 3D, Inc., Fujian Zhongli Co., Ltd., and Tellyes Scientific Co., Ltd.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah

    Coherent Market Insights

    1001 4th Ave,

    #3200

    Seattle, WA 98154

    Tel: +1-206-701-6702

    Email: sales@coherentmarketinsights.com


  • Biomarkers Market - Industry Insights, Size, Share, and Forecast 2017-2025

    In order to cater to growing demand manufacturers are focusing on research & development for new product launches. For instance, in March 2017, the GeneNEWS Limited launched BreastSentry, a new risk stratification test for breast cancer. The BreastSentry incorporates a blood-based biomarker test to determine a woman’s five year and lifetime risk for developing breast cancer. Furthermore, in February 2018, Genomic Health, Inc. announced commercial launch of the Oncotype DX AR-V7 Nuclus Detect test in the U.S. The test consists of AR-V7 protein, a prognostic and predictive biomarker, used for detection of tumor cells and to provide precise treatments for cancer.

    Millipore Sigma, in May 2017, launched a new single molecule counting platform, SMCxPROTM, during the American Association for Cancer Research Annual Meet. The SMCxPRO platform allows researchers to detect or monitor changes in biomarkers, even at extremely low concentration. Such advancement in the biomarker tests is expected to foster growth of the biomarkers in the near future.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1530

    Furthermore, governments of various countries are focusing on initiatives, in order to develop novel techniques in precision medicines. For instance, the U.S. government launched Precision Medicine Initiative (PMI) in 2015, in order to increase awareness and focus on advancements in precision medicine field, which in turn, favors growth of the biomarkers market.

    FDA Biomarker Qualification Program was established in 2009 to support the Center for Drug Evaluation and Research’s (CDER's) work with external stakeholders to develop biomarkers that aid in drug development process. Biomarkers are widely used in drug development to improve the success rate and cost effectiveness.

    Hence, pharmaceutical companies are increasingly outsourcing complex bio analysis to cut down on costs as well as to benefit from specialized expertise from the outsourced companies. This in turn, is enhancing efficiency of the drug development process. For instance, in March 2018, the SenzaGen entered into a license agreement with Burlesson Research Technologies, Inc., (BRT), a contract research organization in the U.S., specializing in immunotoxicology.

    Precision Medicine Initiative have led to development of novel drugs and new treatments, tailored for specific characteristic such as person’s genetic makeup or genetic profile of an individual tumor that helps to transform the way of treatment. This also favors growth of the biomarkers market in the near future. As for the development of precision medicine, it is essential to identify biomarkers.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1530

     

    Some of the major players involved in the global biomarkers market include Abbott Laboratories, Medtronic, BG Medicine, Inc., F. Hoffman LA Roche Ltd., Seimens Healthnineers, Nexus-DX, Qiagen N.V., and Lifesign LLC.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Test Phantom Market - Size, Share, Outlook, and Analysis, 2018-2026

    A test phantom is readily available and offers more reliable results than the use of human volunteers. Various test phantoms are available in the market such as CT test phantom, mammography test phantom, ultrasound test phantom, radiation oncology test phantom, and MRI test phantoms. Each type of the test phantom offers diverse information about the body part being examined for injury or disease treatment. Recent advances in test phantom techniques provide a better non-invasive solution for identifying various chronic diseases and treatment associated with it.

    Request a sample copy for Industry Insight: https://www.coherentmarketinsights.com/insight/request-sample/2287

    Increasing prevalence of various chronic diseases such as HIV, tuberculosis, and cancer is expected to contribute to significant growth of the test phantom market. For instance, according to the World Health Organization key fact 2018, cancer was the second leading cause of death worldwide and was responsible for 8.8 million deaths in 2015. Moreover, medical imaging is one of the important parts of healthcare industry, as nearly all the diagnostics and treatment are based upon the analysis provided by the imaging techniques.

    Increasing use of imaging techniques in the healthcare sector is expected to propel growth of the test phantom market. For instance, according to National Health Services (U.K.) diagnostic imaging dataset statistical release, around 41 million medical imaging tests were reported in England in 2017, 3.49 million imaging tests were recorded in January 2017, with radiograph being performed 1.89 million times, followed by diagnostic ultrasonography (Ultrasound, 0.77 million), computerized axial tomography (CT scan, 0.40 million), and magnetic resonance imaging (MRI, 0.28 million).

    Furthermore, government funding for enhanced imaging solutions is expected to significantly boost the market growth. For instance, in 2014, the U.K Government funded US$ 27,327,000 to build an Imaging Center for Excellence (ICE) at the University of Glasgow. However, high maintenance cost related with medical test phantoms is expected to hamper the market growth.

    Increasing research and development activities in imaging technologies in the region. Moreover, increasing use of diagnostic services by healthcare facilities is expected to propel growth of the market. For instance, according to National Science and Technology Council 2017 report, 79 million CT scans, 39 million MRI scans, and 1.7 million PET scans were performed in the U.S in 2015.

    Purchase this Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/2287

    Major players operating in the test phantom markets include, Fluke Corporation, IBA, Sun Nuclear Corporation, Biodex Medical Systems, Standard Imaging, Capintec, Pro-Project, The Phantom Laboratory, RaySafe, Carville, CIRS, Kyoto Kagaku Co., Ltd, Modus Medical Devices, Radiology Support Devices, and 3-Dmed.

    Key players are focused on adopting market strategies such as collaboration, mergers, and new product launch in order to retain dominant position in the market. For instance, in 2014, Kyoto Kagaku Co., Ltd launched Female Pelvis Ultrasound Phantom US-14a and US-14b, it has features such as accurate cerebral anatomy just like human brain.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Levodopa Market - Size, Share, Outlook, and Analysis by 2018-2026

    Development of novel formulations and efficient drug delivery methods for levodopa are expected to drive growth of the levodopa market. For instance, a clinical study for gastric retentive Accordion Pill, an immediate drug release formulation by Intec Pharma Ltd., is ongoing in clinical phase III and is expected to complete in September 2018. Accordion Pill is a Carbidopa/Levodopa (AP-CD/LD) combinational oral drug delivery system, which is designed to improve the efficacy and safety of existing CD/LD drugs by utilizing an efficient gastric retention and specific release mechanism.

    Moreover, Impel NeuroPharma Inc. is conducting phase II clinical study for INP103, a drug-device combination product containing a drug component, L-dopa, and device component I231 Precision Olfactory Delivery (POD) device. The study is expected to complete in November 2018.

    Get Request sample copy for Industry Insight: https://www.coherentmarketinsights.com/insight/request-sample/2247

    Furthermore, advancement in diagnosis of Parkinson's disease (PD) progression is expected to boost growth of levodopa market. For instance, a clinical study conducted by Washington University School of Medicine, for measuring PD progression both by using Magnetic Resonance Imaging (MRI) and by controlled dose of levodopa for discovering suitable biomarker of PD is currently in clinical phase I and is expected to complete in February 2019.

    Shortage of drug supply in the market due to delay in manufacturing and supply of levodopa is expected to hamper levodopa market growth. For instance, Merck Sharp & Dohme Ireland (Human Health) Ltd. in September 2018, anticipated stock shortage of some Sinemet (Carbidopa/ Levodopa) products in the Irish market in near future due to global manufacturing delays in production and demand for resupply of these products.

    North America is expected to dominate the global levodopa market, owing to approval of new products by the U.S. Food and Drug Administration (FDA). For instance, in 2015, FDA approved an extended-release oral formulation of Levodopa/Carbidopa called Duopa, manufactured by AbbVie Inc., in the U.S. market. Duopa is a gel formulation of Carbidopa/Levodopa enteral suspension and is administered using a small, portable infusion pump that delivers Carbidopa and Levodopa directly into the small intestine, which continuously release over 16 hours in the body.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2247

    Europe region is expected to witness significant growth in levodopa market due to involvement of key players for marketing novel formulations in European region. For instance, Acorda Therapeutics, Inc., in March 2018, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA, an investigational inhaled levodopa treatment for symptoms of OFF periods (OFF symptoms implies recurrence of symptoms such as rigidity, and tremors after long period of levodopa use) in people with PD taking a Carbidopa/Levodopa regimen.

    The key players operating in levodopa market include, Taj Pharmaceuticals Limited., Guangzhou HanFang Pharmaceutical Company Limited, Poulvet.com, Teva Pharmaceutical Industries Ltd., UBM, Zhejiang Wild Wind Pharmaceutical Co., Ltd., and SWAPNROOP.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah

    Coherent Market Insights

    1001 4th Ave,

    #3200

    Seattle, WA 98154

    Tel: +1-206-701-6702

    Email: sales@coherentmarketinsights.com


  • Ultrasonic Aspirator Market Size, Share, Outlook, and Analysis 2018-2026

    Increasing incidences of gynecologic cancer and rapid use of ultrasonic aspirators in surgical cytoreduction procedures in cancer treatment is expected to fuel growth of the ultrasonic aspirators market during forecast period. For instance, in 2018, according to the American Cancer Society’s estimation, about 110,070 new cases of gynecologic cancer were diagnosed and about 32,120 deaths associated with gynecologic cancers were reported in the U.S.

    Get Request sample copy for Industry Insight: https://www.coherentmarketinsights.com/insight/request-sample/2446

    Manufacturers are engaged in acquisition activities to strengthen its product portfolio. For instance, in April 2018, Olympus announced plans to acquire lithotripsy system including ShockPulse-SE and CyberWand manufactured by Cybersonics, Inc. CyberWand is a dual probe electromechanical device capable of fragmenting and aspirating calculi in kidney, bladder, or ureter.

    Moreover, increasing prevalence of neurological disorders is expected to increase demand for ultrasonic aspirators to gain substantial growth in the global ultrasonic aspirator market. For instance, as per Global Burden of Disease (GBD) estimation, neurological disorders contributed to 6.3% (94,608 case of neurological disorder) of the global burden of diseases in 2015.

    A long with neurosurgery, ultrasonic aspiration is beneficial in various general surgical applications such as partial pancreatectomy, liver lobectomy, pyloric surgery, cholecystectomy, various benign/malignant masses, adrenalectomy, and nephrectomy/partial nephrectomy.

    Furthermore, increasing number of research involved in the utilization of the ultrasonic aspirator to enable removal of the tumors in specific body parts will propel the overall market growth during the forecast period. For instance, in 2018, as per published report in Open Researcher and Contributor ID (ORCiD), researchers at Neurosurgery Department, Regional University Hospital, Carlos Haya Avenue, Malaga, Spain, introduced a series of nine consecutive cases of purely endoscopic resection of intraventricular tumors with the help of an ultrasonic aspirators specific for neuroendoscopy.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2446

    Key players operating in the ultrasonic aspirator market include Stryker Corporation, Olympus Pvt. Ltd., Integra LifeSciences, B. Braun Melsungen AG, Sring GmbH, Biomedicon Systems India Pvt Ltd, Xcellance Medical Technologies, Misonix, Cybersonics, Inc., Meta Dynamic, Inc., and InnoSound Technologies, Inc.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Cytotoxic Drugs Market Size, Share, Outlook, and Analysis, 2018-2026

    The cytotoxic drugs market size is expected to grow significantly during the forecast timeframe, owing to increasing incidences of cancer worldwide. According to World Health Organization’s (WHO) 2018 report, around 9.6 million deaths were recorded due to cancer and around 18.1 million new cases of cancer were diagnosed in 2018 worldwide.

    Furthermore, increasing number of cytotoxic drug approvals is expected to boost the market growth. For instance, in November 2018, the U.S. FDA approved Pfizer’s DAURISMO (glasdegib) in the U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom intensive chemotherapy is not an option. Other potential factor that contributes to cytotoxic drugs market revenue growth is increasing therapeutic area of cytotoxic drugs in auto-immune conditions, rheumatoid arthritis, psoriasis, or prevention of transplant rejection because of its immunosuppressive or anti–proliferative effects.

    Get Request sample copy for Industry Insight: https://www.coherentmarketinsights.com/insight/request-sample/2533

    The major restraining factor for the cytotoxic drugs market growth is adverse side effects shown by consumption of cytotoxic drugs such as nausea and vomiting, severe diarrhea, and damage to bone marrow. Cytotoxic drugs can be toxic to other organ systems and lead to conditions such as gastrointestinal toxicity, neurotoxicity renal toxicity, and cardiovascular toxicity. For instance, according to NHS Lothian Joint Formulary, drugs such as fluorouracil, doxorubicin, and oral capecitabine may cause severe stomatitis, diarrhea, and coronary spasm mimicking angina. Moreover, systemic anti-cancer therapy (SACT) drugs increase the risk of thromboembolic disease eventually restraining the cytotoxic drugs market growth.

    North America is expected to hold a dominant position in the cytotoxic drugs market over the forecast period, owing to increasing awareness and availability of wide range of cytotoxic drugs in the region. According to a study published in National Center for Biotechnology Information (NCBI) in 2017, the U.S. Food and Drug Administration has approved 61 cytotoxic drugs for cancer, which help in increasing the survival rates of cancer patients.

    Asia Pacific cytotoxic drugs market size is expected to witness significant growth, owing to large patient base and increasing healthcare insurance schemes in the region. For instance, in 2018, the Government of India launched Pradhan Mantri Jan Arogya Yojana (PMJAY) to provide health insurance worth US$ 7,124.54 to over 100 million families, annually.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2533

    Key players operating in the global cytotoxic drugs market include, Eli Lilly and Company, Sanofi S.A., F. Hoffmann-La Roche Ltd, Pfizer Inc., Celgene Corporation, Amgen Inc., Novartis AG Merck and Co., Johnson and Johnson, and GlaxoSmithKline Plc.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah

    Coherent Market Insights

    1001 4th Ave,

    #3200

    Seattle, WA 98154

    Tel: +1-206-701-6702

    Email: sales@coherentmarketinsights.com


  • Cell-based Assay Market Size, Share, Trends, Outlook, and Analysis, 2018-2026

    DiscoverX Corporation launched in-cell pulse cell-based assays for confirmation of compound-target engagement in drug discovery. DiscoverX Corporation, one of the leading supplier of cell-based assay in 2016 introduced InCELL Pulse target engagement platform that provides scientists with the ability to generate their own cell-based target engagement assays for confirming compound cell entry and target binding in the native cellular environment.

    Request Sample Copy of this Report: www.coherentmarketinsights.com/insight/request-sample/1273

     

    Rapid growth in drug discovery is expected to increase the demand for cell-based assay as it is mainly used in checking toxicity of drugs. For instance according to FDA’s Center for Drug Evaluation and Research (CDER) in 2016, CDER approves averagely 30 novel drugs per year and the development of novel drug discovery is expected to increase in future. Many companies are involved in the drug discovery needs cell-based assay for testing new drugs that is expected to boost the cell-based assay market in forecast period.

    Since pharmaceutical market have become a billion-dollar business, many pharmaceutical and biotechnological companies are adopting cell-based assay in order to reduce the chances of failure of batch which lead to a high loss to company. Thus, the adoption of this method by companies is expected to fuel its market in near future. However, high maintenance, need for skilled personnel and high-cost of operation for the cell based assays are expected to hinder the market growth.

    The cell-based assay market due to rapid growth of pharmaceutical and biotechnology manufacturing sector. According to a study published in International Trade Administration in 2016, U.S. is a major hub for drug manufacturing and the market is expected to grow drastically in future which is expected to fuel cell-based assay market in North America. Asia pacific is expected to follow North America market in upcoming period of time due to increase in pharmaceutical and biotechnological sector in China and India which will increase the demand for cell-based assay and fuel its market in forecast period.

    Cell-based assays provides accuracy in obtaining the data of various parameters of the real-life model as live cells are used, cell-based assays are now used in drug discovery and checking the toxicity of new or old drugs used by population. With the rapid growth of pharmaceutical and biotechnological sector worldwide and emerging development of new drugs, the demand for cell-based assay is expected to witness a rapid increase. Companies are adopting the cell-based assay order to reverse the costly late-stage drug failure and thus the rising surge of cell-based assay is expect to have a positive effect on market growth in near future.

    Get PDF Brochure of Research Report: www.coherentmarketinsights.com/insight/request-pdf/1273

    Major key players in cell-based assay market are DiscoverX Corporation, Becton, Dickinson and Company, cell Signaling Technology, Inc., Becton, Danaher Corporation, Thermo Fisher Scientific, Inc., Cisbio Bioassays, Merck & Co., Qingdao Haier Co., and PerkinElmer, Inc. and others.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah

    Coherent Market Insights

    1001 4th Ave,

    #3200

    Seattle, WA 98154

    Tel: +1-206-701-6702

    Email: sales@coherentmarketinsights.com


  • Cell Counting Devices Market Size, Share, Outlook, and Analysis, 2018-2026

    Cell counting is a technique used for determining physical properties of cells such as concentration, density, and viability. Cell counting method is adopted by doctors also, so as to know the condition of the patient. They use this method for estimating the concentration of white blood cells, red blood cells, platelets, etc. and the amount of it tells the health status of patients. Cells counting can be done either manually through hemocytometer where in the volumetric grid of it is used for estimating the concentration of cells, or by plating the microbes into petri dish containing growth medium.

    Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2710

    Key players are focused on developing new products for cell counting, which is expected to propel the global cell counting devices market growth. For instance, in January 2019, DeNovix Inc. launched a product, Cell Drop Automated Cell Counter for analysis of cell culture. It has dual fluorescence and bright-field optics, and also, easy to use analyzer. It includes direct pipette technology, which ensures precise and accurate cell suspension. It does not require any calibration. It is designed with the aim to eliminate the slides and the complex method of hemocytometer.

    Moreover, key players also actively involved in participating in conferences and events related to cell counting device. For instance, in February 2019, BioRad Laboratories Inc. participated in Society for Laboratory Automation and Screening 2019 (SLAS), held in Washington D.C., wherein it showcased its product, ZE5 cell analyzer. It consists a robotic arm, which ensures precise and accurate measurements of additions of reagents and also enables easy integration of fluids. It is capable of processing 96 or 384 plates under 60 minutes.

    In 2017, GE Healthcare, a company that designs imaging and monitoring systems entered into a partnership with Guangzhou RiboBio Co., Ltd., a biotechnology company to establish oligonucleotide drug development and manufacturing facility in China. GE healthcare provided all the advanced instruments, which also includes IN Cell Analyzer 6500H, while Guangzhou RiboBio supported the infrastructure and provided with the staff. IN Cell Analyzer 6500H is an imaging system based on IRIS confocal technology. Its features live cell imaging, three dimensional imaging, and higher throughput.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2710

    Moreover, in April 2019, Nexcelom Bioscience, a manufacturer of cell counting and characterization products released Cellaca MX. It is an automated cell counter consisting of bright field and fluorescence imaging cytometry. Around 24 samples can be processed in 48 seconds allowing high throughput and high speed. Hence, these factors are expected to drive the global cell counting devices market growth.

    Major players operating in the global cell counting devices market include Paul Marienfeld GmbH & Co. KG, ChemoMetec A/S, BioTek Instruments, Inc., Becton, Dickinson and Company, Tip Biosystems, Corning Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., GE Healthcare, and Thermo Fisher Scientific

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


connect